Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression

Journal of Clinical Oncology

Volumn 25, Issue 25, 2007, Pages 3892-3901

  Orlowski, Robert Z ^a   Nagler, Arnon ^b   Sonneveld, Pieter ^b   Bladé, Joan ^b   Hajek, Roman ^b   Spencer, Andrew ^b   San Miguel, Jesús ^b   Robak, Tadeusz ^b   Dmoszynska, Anna ^b   Horvath, Noemi ^b   Spicka, Ivan ^b   Sutherland, Heather J ^b   Suvorov, Alexander N ^b   Zhuang, Sen H ^b   Parekh, Trilok ^b   Xiu, Liang ^b   Yuan, Zhilong ^b   Rackoff, Wayne ^b   Harousseau, Jean Luc ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DOXORUBICIN; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DRUG DERIVATIVE; MACROGOL DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAZARD RATIO; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG RESISTANCE; HEMATOLOGIC DISEASE; MIDDLE AGED; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; POLYETHYLENE GLYCOLS; PYRAZINES;

EID: 34548539381     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.10.5460     Document Type: Article

References (26)

1. Orlowski RZ, Eswara JR, Lafond-Walker A, et al: Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 58:4342-4348, 1998
2. Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076, 2001
3. LeBlanc R, Catley LP, Hideshima T, et al: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62:4996-5000, 2002
4. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427, 2002
5. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
6. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005
7. Voorhees PM, Dees EC, O'Neil B, et al: The proteasome as a target for cancer therapy. Clin Cancer Res 9:6316-6325, 2003
8. Rajkumar SV, Richardson PG, Hideshima T, et al: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23:630-639, 2005
9. Ma MH, Yang HH, Parker K, et al: The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9:1136-1144, 2003
10. Mitsiades N, Mitsiades CS, Richardson PG, et al: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 101:2377-2380, 2003
11. Small GW, Shi YY, Edmund NA, et al: Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role. Mol Pharmacol 66:1478-1490, 2004
12. Hideshima T, Mitsiades C, Akiyama M, et al: Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101:1530-1534, 2003
13. Mitsiades N, Mitsiades CS, Poulaki V, et al: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 99:14374-14379, 2002
14. Small GW, Somasundaram S, Moore DT, et al: Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK. J Pharmacol Exp Ther 307:861-869, 2003
15. Orlowski RZ, Voorhees PM, Garcia RA, et al: Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105:3058-3065, 2005
16. Biehn SE, Moore DT, Voorhees PM, et al: Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 86:211-216, 2007
17. Berenson JR, Hillner BE, Kyle RA, et al: American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol 20:3719-3736, 2002
18. Bladé J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT - European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123, 1998
19. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979
20. Durie BG, Harousseau JL, Miguel JS, et al: International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473, 2006
21. Kyle RA, Rajkumar SV: Multiple myeloma. N Engl J Med 351:1860-1873, 2004
22. Jagannath S, Durie BG, Wolf J, et al: Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129:776-783, 2005
23. Jagannath S, Richardson PG, Barlogie B, et al: Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 91:929-934, 2006
24. Jakubowiak AJ, Brackett L, Kendall T, et al: Combination therapy with Velcade, Doxil, and dexamethasone (VDD) for patients with relapsed/refractory multiple myeloma (MM). Proc Am Soc Hematol 106, 2005 (abstr 5179)
25. Rajkumar SV, Blood E, Vesole D, et al: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24:431-436, 2006
26. Weber D, Wang M, Chen C, et al: Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of 2 Phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function. Proc Am Soc Hematol 108, 2006 (abstr 3547)